IL-5-producing CD4 + T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer

Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between innate and adaptive immune cells. Here, we combine...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell Vol. 41; no. 1; p. 106
Main Authors: Blomberg, Olga S, Spagnuolo, Lorenzo, Garner, Hannah, Voorwerk, Leonie, Isaeva, Olga I, van Dyk, Ewald, Bakker, Noor, Chalabi, Myriam, Klaver, Chris, Duijst, Maxime, Kersten, Kelly, Brüggemann, Marieke, Pastoors, Dorien, Hau, Cheei-Sing, Vrijland, Kim, Raeven, Elisabeth A M, Kaldenbach, Daphne, Kos, Kevin, Afonina, Inna S, Kaptein, Paulien, Hoes, Louisa, Theelen, Willemijn S M E, Baas, Paul, Voest, Emile E, Beyaert, Rudi, Thommen, Daniela S, Wessels, Lodewyk F A, de Visser, Karin E, Kok, Marleen
Format: Journal Article
Language:English
Published: United States 09.01.2023
Subjects:
Animals
Antigen Presentation
CD4-Positive T-Lymphocytes - pathology
CD8-Positive T-Lymphocytes
Eosinophils - pathology
Immune Checkpoint Inhibitors - therapeutic use
Interleukin-33
Interleukin-5 - therapeutic use
Mice
Neoplasms - drug therapy
myeloid cells
CD4(+) T cells
IL-5
breast cancer
eosinophils
IL-33
immune checkpoint blockade
ISSN:1878-3686, 1878-3686
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between innate and adaptive immune cells. Here, we combine unbiased analysis of blood and tumors from metastatic breast cancer patients treated with ICB with mechanistic studies in mouse models of breast cancer. We observe an increase in systemic and intratumoral eosinophils in patients and mice responding to ICB treatment. Mechanistically, ICB increased IL-5 production by CD4 T cells, stimulating elevated eosinophil production from the bone marrow, leading to systemic eosinophil expansion. Additional induction of IL-33 by ICB-cisplatin combination or recombinant IL-33 promotes intratumoral eosinophil infiltration and eosinophil-dependent CD8 T cell activation to enhance ICB response. This work demonstrates the critical role of eosinophils in ICB response and provides proof-of-principle for eosinophil engagement to enhance ICB efficacy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccell.2022.11.014